Jefferies reiterates Buy on Piramal Pharma with a target price of ₹190.
Q4 in line; FY27 guidance shows strong CDMO momentum despite EBITDA estimate cuts for FY27-28.
Livesquawk •
Piramal Pharma projects net debt to EBITDA at 3.6x for FY27.
The company aims to reduce leverage to 1x in the long term.
Livesquawk •
Piramal Pharma projects FY27 CapEx at INR120-135M for Lexington expansion.
The Lexington expansion is targeted for completion by end of CY27.
Piramal Pharma highlights ADC outlook, citing conjugation services as key revenue driver.
Conjugation services support CDMO selection over mAb providers, per concall update.
Livesquawk •
Piramal Pharma sees growth momentum with new customers and Phase 3 ADC additions.
The company is expanding its antibody drug conjugate (ADC) pipeline per concall update.